

## THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. The revised classification of myelodysplastic syndromes (MDS) by the World Health Organization now includes MDS with ring sideroblasts (MDS-RS), including MDS-RS with single and multiple dysplasia, as a categorized subtype.**
  - a. True
  - b. False
- 2. The mechanism of action of sotatercept is \_\_\_\_\_.**
  - a. IDH inhibition
  - b. Immune checkpoint inhibition
  - c. TGF- $\beta$  inhibition
- 3. Which of the following patients with lower-risk MDS who have not yet required blood transfusions are more likely to respond to erythropoiesis-stimulating agents?**
  - a. Those with higher erythropoietin levels
  - b. Those with lower erythropoietin levels
  - c. Both respond similarly
- 4. The rate of cure for patients with MDS undergoing transplantation is approximately 30% to 40%, whereas the mortality rate associated with transplantation is 1% to 3%.**
  - a. True
  - b. False
- 5. In the Phase III MDS-004 study evaluating lenalidomide at 10 mg for patients with lower-risk MDS and del(5q) who are blood transfusion dependent, approximately what percent of patients achieved a transfusion independence response with lenalidomide treatment?**
  - a. Less than 20%
  - b. 40%
  - c. 60%
- 6. The Phase II PACE-MDS study investigating luspatercept for patients with lower-risk MDS showed a higher response rate of approximately 60% in patients without ring sideroblasts versus those with ring sideroblasts.**
  - a. True
  - b. False
- 7. What is the response rate observed in patients with lower-risk MDS who receive hypomethylating agents?**
  - a. Less than 10%
  - b. 30% to 40%
  - c. More than 60%
- 8. Approximately what percent of patients with MDS have isocitrate dehydrogenase (IDH) mutations?**
  - a. More than 70%
  - b. 50%
  - c. 6% to 8%
- 9. The MDS-005 study comparing lenalidomide to placebo for patients with lower-risk MDS without del(5q) demonstrated that approximately 25% of patients achieve RBC transfusion independence after 8 weeks with lenalidomide.**
  - a. True
  - b. False
- 10. Which of the following patients with MDS and otherwise similar prognostic indicators are likely to experience better treatment outcomes?**
  - a. Patients with a secondary therapy-related myeloid neoplasm
  - b. Patients with a primary de novo myeloid neoplasm
  - c. Outcomes are similar for both groups